Feb 28, 2026

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Antibody-Drug Conjugates for Breast Cancer | Faculty Presentation 1: Current and Emerging Role of HER2-Directed Antibody-Drug Conjugates (ADCs) — Hope S Rugo, MD

CME information and select...

Feb 27, 2026

Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics:

• Introduction: Rational Treatment Goals for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)? (0:00)
• Current Considerations in the Selection of First-Line and Maintenance Therapy — Dr Borghaei (8:13)
• Case: A woman...

Feb 26, 2026

Featuring an interview with Dr Stacey A Cohen, Dr Arvind Dasari and Dr Christopher Lieu, including the following topics:

• Biological Principles Underlying Circulating Tumor DNA (ctDNA) Molecular Residual Disease (MRD) Testing in Colorectal Cancer (CRC) — Dr Cohen (0:00)
• Potential Utility of ctDNA Testing to Identify...

Feb 23, 2026

Featuring an interview with Dr Terence Friedlander, including the following topics:

• Perioperative durvalumab with neoadjuvant chemotherapy: Health-related quality-of-life outcomes in the NIAGARA trial (0:00)
• Targeting HER2 in locally advanced or metastatic urothelial carcinoma (5:17)
• TROP2-targeted antibody-drug...

Feb 18, 2026

Featuring perspectives from Dr Natalie S Callander and Dr Paul G Richardson, including the following topics:

• Introduction: Clinical Trials We LOVE to Discuss (0:00)
• Mechanism of Action of Cereblon E3 Ligase Modulators (CELMoDs) (8:42)
• Available Efficacy Data with CELMoDs in the Management of Relapsed/Refractory...